Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | ELANE | P08246 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10164962 | 0.87 | F2RL3 (0.64) | F2RL3CYP19A1ELANEMAPK1SMN1; SMN2 | |
| SCHEMBL3785436 | 0.85 | CHRM1 (0.53) | F2RL3ELANEF2PLAUMEN1 | |
| SCHEMBL25966954 | 0.83 | ELANE (0.65) | F2RL3CYP19A1ELANESMN1; SMN2F2 | |
| SCHEMBL15897855 | 0.82 | ELANE (0.58) | F2RL3CYP19A1ELANEMAPK1F2 | |
| SCHEMBL17322915 | 0.82 | ELANE (0.67) | F2RL3CYP19A1ELANEF2PLAU | |
| SCHEMBL957880 | 0.81 | F2RL3 (0.60) | F2RL3ELANEF2PLAUPTGER4 | |
| SCHEMBL19402534 | 0.80 | ELANE (0.56) | F2RL3ELANEF2PLAUPTGER4 | |
| SCHEMBL14875412 | 0.80 | F2RL3 (0.42) | F2RL3CYP19A1ELANESMN1; SMN2POLB | |
| SCHEMBL15897947 | 0.79 | GABRA1 (0.57) | F2RL3ELANEF2PLAU | |
| SCHEMBL16378028 | 0.79 | F2RL3 (0.57) | F2RL3ELANEMAPK1SMN1; SMN2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653079-B2 | Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | F2RL3 396/4885CYP19A1 975/4885ELANE 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.